Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 6, 2014, Pages

  Gobe, Glenda C ^a   Bennett, Nigel C ^a   West, Malcolm ^a   Colditz, Paul ^b   Brown, Lindsay ^c   Vesey, David A ^a,d   Johnson, David W ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Acute kidney injury; Chronic kidney disease; EPO; Erythropoietin; Fibrosis; Ischemia reperfusion

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; COLLAGEN; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL PROTECTION; CELL STIMULATION; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL RENAL FAILURE; FIBROBLAST; FIBROBLAST CULTURE; HISTOPATHOLOGY; HORMONAL THERAPY; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; MALE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CELL CULTURE; CHRONIC KIDNEY DISEASE; DRUG EFFECT; EPO; FIBROSIS; HUMAN; ISCHEMIA-REPERFUSION; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; REPERFUSION INJURY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; CHRONIC KIDNEY DISEASE; EPO; ERYTHROPOIETIN; FIBROSIS; ISCHEMIA-REPERFUSION;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; CELLS, CULTURED; DISEASE PROGRESSION; ERYTHROPOIETIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REPERFUSION INJURY; TREATMENT OUTCOME;

EID: 84900343814     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00241.2013     Document Type: Article

References (74)

1. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141: 14-31, 2008.
2. Askenazi DJ, Feig DI, Graham NM, Hui-Stickle S, Goldstein SL, Hui-Stickle S. 3-5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 69: 184-189, 2006.
3. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, Jaudon MC, Bourbouze R, Jacobs C, Deray G. Erythropoietin enhances recovery after cisplatin_induced acute renal failure in the rat. Nephrol Dial Transplant 16: 932-938, 2001.
4. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E, Güler F, Menne J, Haller H, Fliser D. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110: 1006-1012, 2004.
5. Basile DP, Donohoe DL, Roethe K, Mattson DL. Chronic renal hypoxia after acute ischemic injury: effects of L-arginine on hypoxia and secondary damage. Am J Physiol Renal Physiol 284: F338-F348, 2003.
6. Basile DP, Donohoe D, Roethe K, Osborne JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 281: F887-F899, 2001.
7. Bi B, Guo J, Marlier A, Lin SR, Cantley LG. Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol 295: F1017-F1022, 2008.
8. Bonventre JV. Pathophysiology of AKI: injury and normal and abnormal repair. Contrib Nephrol 165: 9-17, 2010.
9. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6: 484-494, 2005.
10. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 264: 405-432, 2008.
11. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Nat Acad Sci USA 97: 10526-10531, 2000.
12. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Nat Acad Sci USA 100: 4802-4806, 2003.
13. Choi BH, Ha Y, Ahn CH, Huang X, Kim JM, Park SR, Park H, Park HC, Kim SW, Lee M. A hypoxia-inducible gene expression system using erythropoietin 3= untranslated region for the gene therapy of rat spinal cord injury. J Neurosurg Spine 7: 54-60, 2007.
14. Diskin CJ. Erythropoietin, haemoglobin, heart failure, mortality. Eur Heart J 29: 2695, 2008.
15. Efthimiadou A, Pagonopoulou O, Lambropoulou M, Papadopoulos N, Nikolettos NK. Erythropoietin enhances angiogenesis in an experimental cyclosporine A-induced nephrotoxicity model in the rat. Clin Exp Pharmacol Physiol 34: 866-869, 2007.
16. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8: 495-505, 2002.
17. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 77: 1020-1030, 2010.
18. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9, Suppl 5: 18-30, 2004.
19. Gobe G. Identification of apoptosis in kidney tissue sections. Methods Mol Biol 466: 175-192, 2009.
20. Gobe GC, Axelsen RA, Searle JW. Cellular events in experimental unilateral ischemic renal atrophy and in regeneration after contralateral nephrectomy. Lab Invest 63: 770-779, 1990.
21. Gobe GC, Endre ZH, Johnson DW. Administration of erythropoietin and its derivatives in renal disease: advantages, mechanisms and concerns. Drug Discov Today Ther Strateg 4: 79-84, 2007.
22. Hogg N, Browning J, Howard T, Winterford C, Fitzpatrick D, Gobe G. Apoptosis in vascular endothelial cells caused by serum deprivation, oxidative stress and transforming growth factor-beta. Endothelium 7: 35-49, 1999.
23. Hoste EA, Kellum JA, Katz NM, Rosner MH, Haase M, Ronco C. Epidemiology of acute kidney injury. Contrib Nephrol 165: 1-8, 2010.
24. Hu L, Yang C, Zhao T, Xu M, Tang Q, Yang B, Rong R, Zhu T. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. J Surg Res 176: 260-266, 2012.
25. Huang LE, Ho V, Arany Z, Krainc D, Galson D, Tendler D, Livingston DM, Bunn HF. Erythropoietin gene regulation depends on hemedependent oxygen sensing and assembly of interacting transcription factors. Kidney Int 51: 548-552, 1997.
26. Hughes J, Gobe G. Identification and quantification of apoptosis in the kidney using morphology, biochemical and molecular markers. Nephrology (Carlton) 12: 452-458, 2007.
27. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176: 85-97, 2010.
28. Johnson DW, Pat B, Vesey DA, Guan ZR, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 69: 1806-1813, 2006.
29. Johnson DW, Vesey DA, Gobe GC. Erythropoietin protects against acute kidney injury and failure. Open Drug Discov J 1: 41-50, 2009.
30. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 23: 842-852, 2008.
31. Lan R, Geng H, Polichnowski AJ, Singha PK, Saikumar P, McEwen DG, Griffin KA, Koesters R, Weinberg JM, Bidani AK, Kriz W, Venkatachalam MA. PTEN loss defines a TGF-_-induced tubule phenotype of failed differentiation and JNK signaling during renal fibrosis. Am J Physiol Renal Physiol 302: F1210-F1223, 2012.
32. Lane A, Johnson DW, Pat B, Winterford C, Endre Z, Wei M, Gobe GC. Interacting roles of myofibroblasts, apoptosis and fibrogenic growth factors in the pathogenesis of renal tubulo-interstitial fibrosis. Growth Factors 20: 109-119, 2002.
33. Lee SH, Li C, Lim SW, Ahn KO, Choi BS, Kim YS, Moon IS, Kim J, Bang BK, Yang CW. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 25: 64-76, 2005.
34. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Ann Rev Pathol Mech Dis 6: 165-192, 2011.
35. Li J, Vesey DA, Johnson DW, Gobe G. Erythropoietin reduces cisplatininduced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 6: 1944-1950, 2007.
36. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18: 423-435, 2010.
37. Lifshitz L, Tabak G, Gassmann M, Mittelman M, Neumann D. Macrophages as novel target cells for erythropoietin. Haematologica 95: 1823-1831, 2010.
38. Liu H, McTaggart SJ, Johnson DW, Gobe GC. Anti-oxidant pathways are stimulated by mesenchymal stromal cells in renal repair after ischemic injury. Cytotherapy 14: 162-172, 2012.
39. Liu N, Tian J, Wang W, Cheng J, Hu D, Zhang J. Effect and mechanism of erythropoietin on mesenchymal stem cell proliferation in vitro under the acute kidney injury microenvironment. Exp Biol Med 236: 1093-1099, 2011.
40. Loeliger MM, Mackintosh A, De Matteo R, Harding R, Rees SM. Erythropoietin protects the developing retina in an ovine model of endotoxin- induced retinal injury. Invest Ophthalmol Vis Sci 52: 2656-2661, 2011.
41. Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, Ratcliffe PJ. Sites of erythropoietin production. Kidney Int 51: 393-401, 1997.
42. Mori S, Sawada T, Okada T, Kubota K. Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery 143: 556-565, 2008.
43. Noiri E, Nagano N, Negishi K, Doi K, Miyata S, Abe M, Tanaka T, Okamoto K, Hanafusa N, Kondo Y, Ishizaka N, Fujita T. Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol 104: e-e14, 2006.
44. Pagtalunan M, Olson J, Tilney N, Meyer T. Late consequences of acute ischemic injury to a solitary kidney. J Am Soc Nephrol 10: 366-373, 1999.
45. Park SH, Choi MJ, Song IK, Choi SY, Nam JO, Kim CD, Lee BH, Park RW, Park KM, Kim YJ, Kim IS, Kwon TH, Kim YL. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-β-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 18: 1497-1507, 2007.
46. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279: 20655-20662, 2004.
47. Pat BK, Cuttle L, Watters D, Yang T, Johnson DW, Gobe GC. Fibrogenic stresses activate different mitogen-activated protein kinase pathways in renal epithelial, endothelial or fibroblast cell populations. Nephrology (Carlton) 8: 192-200, 2003.
48. Pat B, Yang T, Kong C, Watters D, Johnson DW, Gobe G. Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by anti-oxidants. Kidney Int 67: 931-943, 2005.
49. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, Thiemermann C. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia//reperfusion in the mouse kidney in vivo. Kidney Int 66: 983-989, 2004.
50. Peng F, Zhang B, Wu D, Ingram AJ, Gao B, Krepinsky JC. TGF-_- induced RhoA activation and fibronectin production in mesangial cells require caveolae. Am J Physiol Renal Physiol 295: F153-F164, 2008.
51. Percy CJ, Brown L, Power DA, Johnson DW, Gobe GC. Obesity and hypertension have differing oxidant handling molecular pathways in age-related chronic kidney disease. Mech Ageing Dev 130: 129-138, 2009.
52. Rabb H. Immune modulation of acute kidney injury. J Am Soc Nephrol 17: 604-606, 2006.
53. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Nat Acad Sci USA 95: 4635-4640, 1998.
54. Salahudeen AK, Haider N, Jenkins J, Joshi M, Patel H, Huang H, Yang M, Zhe H. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 294: F1354-F1365, 2008.
55. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157: 907-921, 2009.
56. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115-2124, 2004.
57. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 30: 253-260, 2009.
58. Sorg H, Krueger C, Schulz T, Menger MD, Schmitz F, Vollmar B. Effects of erythropoietin in skin wound healing are dose related. FASEB J 23: 3049-3058, 2009.
59. Spandou E, Tsouchnikas I, Karkavelas G, Dounousi E, Simeonidou C, Guiba-Tziampiri O, Tsakiris D. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 21: 330-336, 2006.
60. Srisawat N, Manotham K, Eiam-Ong S, Katavetin P, Praditpornsilpa K, Eiam-Ong S. Erythropoietin and its non-erythropoietic derivative: do they ameliorate renal tubulointerstitial injury in ureteral obstruction? Int J Urol 15: 1011-1017, 2008.
61. Toba H, Morishita M, Tojo C, Nakano A, Oshima Y, Kojima Y, Yoshida M, Nakashima K, Wang J, Kobara M, Nakata T. Recombinant human erythropoietin ameliorated endothelial dysfunction and macrophage infiltration by increasing nitric oxide in hypertensive 5/6 nephrectomized rat aorta. Eur J Pharmacol 656: 81-87, 2011.
62. Toba H, Nakashima K, Oshima Y, Kojima Y, Tojo C, Nakano A, Wang J, Kobara M, Nakata T. Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis. Clin Exp Pharmacol Physiol 37: 1139-1146, 2010.
63. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C;. Beginning, and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients. JAMA 294: 813-818, 2005.
64. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 298: F1078-F1094, 2010.
65. Vesey DA, Cheung C, Pat B, Gobe GC, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19: 348-355, 2004.
66. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657, 2000.
67. Wong MG, Perkovic V, Woodward M, Chalmers J, Li Q, Hillis GS, Yaghobian Azari D, Jun M, Poulter N, Hamet P, Williams B, Neal B, Mancia G, Cooper M, Pollock CA. Circulating bone morphogenetic protein-7 and transforming growth factor-_1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int 83: 278-284, 2013.
68. Yalavarthy R, Edelstein CL, Teitelbaum I. Acute renal failure and chronic kidney disease following liver transplantation. Hemodial Int 11: S7-S12, 2007.
69. Yamada M, Burke C, Colditz P, Johnson DW, Gobe GC. Erythropoietin protects against apoptosis and increases expression of non-neuronal cell markers in the hypoxia-injured developing brain. J Pathol 224: 101-109, 2011.
70. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45: 916-927, 1994.
71. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, Sun BK, Kim YS, Kim J, Chang YS, Bang BK. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17: 1754-1755, 2003.
72. Yang T, Vesey DA, Johnson DW, Wei MQ, Gobe GC. Apoptosis of tubulointerstitial chronic inflammatory cells in progressive renal fibrosis after cancer therapies. Transl Res 150: 40-50, 2007.
73. Yang T, Zhang B, Pat BK, Wei MQ, Gobe GC. Lentiviral-mediated RNA interference against TGF-beta receptor type II in renal epithelial and fibroblast cell populations in vitro demonstrates regulated renal fibrogenesis that is more efficient than a nonlentiviral vector. J Biomed Biotechnol 859240, 2010.
74. Zhang X, Li QY, Xiao BG. Anti-inflammatory effect of erythropoietin therapy on experimental autoimmune encephalomyelitis. Int J Neurosci 122: 255-262, 2012.